Topical non-steroidal anti-inflammatory drugs in treatment of osteoarthritis


DOI: https://dx.doi.org/10.18565/therapy.2020.8.186-190

Gaydukova I.Z., Mazurov V.I.

I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia, Saint Petersburg
Osteoarthritis is one of the most common rheumatic diseases in which inflammation plays an important role, affecting all structural elements of the joint. Reducing inflammation with oral nonsteroidal anti-inflammatory drugs (NSAIDs) is difficult for a number of objective reasons, the most important of which is poor penetration of systemic NSAIDs into the avascular tissues of the joint and limitations the use of NSAIDs in patients with co-morbidities. In this regard, the most promising agents used to reduce inflammation (pain) are topical NSAIDs, which, according to international and Russian sources, can be effective and safe for a large number of patients with osteoarthritis. A number of controlled comparative studies have shown that diclofenac sodium is effective as an emulsifier. It is important to note that topical NSAIDs have been shown to be effective both as monotherapy and in combination with systemic NSAIDs. Thus topical NSAIDs can be an effective and safe adjunct to the treatment or an alternative to systemic NSAIDs in the treatment of osteoarthritis.
Keywords: diclofenac sodium, systemic NSAIDs, co-morbid conditions, topical NSAIDs, osteoarthritis
Read entire article

Literature


  1. Галушко Е.А., Насонов Е.Л. Распространенность ревматических заболеваний в России. Альманах клинической медицины. 2018; 1: 32–39. [Galushko E.A., Nasonov E.L. Prevalence of rheumatic diseases in Russia. Al'manakh klinicheskoy meditsiny. 2018; 1: 32–39 (In Russ.)]. doi: 10.18786/2072-0505-2018-46-1-32-39.

  2. Wesseling J., Welsing P.M., Bierma-Zeinstra S.M. et al. Impact of self-reported comorbidity on physical and mental health status in early symptomatic osteoarthritis: the CHECK (Cohort Hip and Cohort Knee) study. Rheumatology. 2013; 52(1): 180–88. doi: 10.1093/rheumatology/kes288.

  3. Pihl K., Roos E.M., Taylor R.S. et al. Associations between comorbidities and immediate and one-year outcomes following supervised exercise therapy and patient education - a cohort study of 24,513 individuals with knee or hip osteoarthritis. Osteoarthritis Cartilage. 2020; S1063–4584(20)31166-3. doi: 10.1016/j.joca.2020.11.001.

  4. Гайдукова И.З., Мазуров В.И., Инамова О.В. Магнитно-резонансная томография как дополнительный инструмент выбора терапии при лечении остеоартрита. РМЖ. 2020; 11: 43–48. [Gaydukova I.Z., Mazurov V.I., Inamova O.V. Magnetic resonance imaging as an additional tool for treatment tactics for osteoarthritis. Russkiy meditsinskiy zhurnal. 2020; 11: 43–48 (In Russ.)].

  5. Bruyere O., Honvo G., Veronese N. et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019; 49(3): 337–50. doi: 10.1016/j. semarthrit.2019.04.008.

  6. Bannuru R.R., Osani M.C., Vaysbrot E.E. et al. OARSI Recommendations for the Management of Hip and Knee Osteoarthritis, Part II: OARSI Evidence-Based, Expert Consensus Guidelines. Osteoarthritis Cartilage. 2019; 27(11): 1578–89. doi: 10.1016/j.joca.2019.06.011.

  7. Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т. с соавт. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018; 56 (прил. 1): 1–29. [Karateev A.E., Nasonov E.L., Ivashkin V.T. et al. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Nauchno-prakticheskaya revmatologiya. 2018; 56 (Suppl. 1): 1–29 (In Russ.)]. doi: 10.14412/1995-4484-2018-1-29.

  8. Мазуров В.И., Трофимов Е.А., Лесняк О.М., Беляева И.Б. Ревматология. Фармакотерапия без ошибок. Руководство для врачей. М.: Е-ното. 2017; 528 с. [Mazurov V.I., Trofimov E.A., Lesnyak O.M., Belyaeva I.B. Rheumatology. Pharmacotherapy without errors. A guide for doctors. Moscow: E-noto. 2017; 528 p. (In Russ.)].

  9. Гайдукова И.З., Мазуров В.И. Эффективность нестероидных противовоспалительных препаратов. Журнал неврологии и психиатрии им. C.C. Корсакова. 2019; 119(5): 134–140. [Gaydukova I.Z., Mazurov V.I. The efficacy of non-sreroidal anti-inflammatory drugs. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2019; 119(5): 134–140 (In Russ.)]. doi: 10.17116/jnevro2019119051134.

  10. Лила А.М., Алексеева Л.И., Бабаева А.Р. и др. Возможности фармакологического лечения остеоартрита: фокус на симптоматические медленно действующие препараты (SYSADOA) и индивидуальные особенности пациента. Резолюция Международного совещания экспертов. Современная ревматология. 2019; 13(4): 143–147. [Lila A.M., Alekseeva L.I., Babaeva A.R. et al. Pharmacological treatment options for osteoarthritis: focus on symptomatic slow-acting drugs for osteoarthritis (SYSADOA) and individual patient characteristics: Resolution of the International Expert Meeting. Sovremennaya revmatologiya. 2019; 13(4): 143–147 (In Russ.)]. doi: 10/14412/1996-7012-2019-4-143-147.

  11. Лазебник Л.Б., Голованова Е.В., Алексеенко С.А. с соавт. Рекомендации по профилактике и лечению эзофаго-гастро-энтеро-колопатий, индуцированных нестероидными противовоспалительными препаратами. Экспериментальная и клиническая гастроэнтерология. 2018; 3: 4–18. [Lazebnik L.B., Golovanova E.V., Alekseenko S.A. et al. Recommendations for the prevention and treatment of esophago-gastro-entero-colopathy induced by nonsteroidal antiinflammatory drugs «NSAID». Experimental'naya i klinicheskaya gastroenterologiya. 2018; 3: 4–18 (In Russ.)].

  12. Derry S., Conaghan P., Da Silva J.A.P. et al. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2016; 4(4): CD007400. doi: 10.1002/14651858.CD007400.pub3.

  13. Lim C.C., Wee Ang A.T., Abdul Kadir H.B. et al. Short-course systemic and topical non-steroidal anti-inflammatory drugs: impact on adverse renal events in older adults with co-morbid disease. Drugs Aging. 2020. doi: 10.1007/s40266-020-00824-4.

  14. Moore R.A., Barden J., Derry S., McQuay H.J. Managing potential publication bias. In: McQuay H.J., Kalso E., Moore R.A. editor(s). Systematic reviews in pain research: methodology refined. Seattle: IASP Press. 2008; 407 p. ISBN: 9780931092695.

  15. Evans J.M., McMahon A.D., McGilchrist M.M. et al. Topical non steroidal anti inflammatory drugs and admission to hospital for upper gastrointestinal bleeding and perforation: a record linkage case control study. BMJ. 1995; 311(6996): 22–26. doi: 10.1136/bmj.311.6996.22.

  16. Simon L.S., Grierson L.M., Naseer Z. et al. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain. 2009; 143(3): 238–45. doi: 10.1016/j.pain.2009.03.008.

  17. Tugwell P.S., Wells G.A., Shainhouse J.Z. Equivalence study of a topical diclofenac solution (Pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol. 2004; 31(10): 2002–12.

  18. Zacher J., Burger K.J., Farber L. et al. Topical diclofenac versus oral ibuprofen: a double blind, randomized clinical trial to demonstrate efficacy and tolerability in patients with activated osteoarthritis of the finger joints (Heberden and/or Bouchard arthritis). Aktuelle Rheumatologie. 2001; 26: 7–14.

  19. Инструкция по применению препарата Вольтарен Эмульгель. РУ П N016030/01. http://grls.rosminzdrav.ru/ (дата обращения – 01.11.2020). [Patient information leaflet for use of Voltaren Emulgel. П N016030/01. http://grls.rosminzdrav.ru/ (date of access – 01.11.2020) (In Russ.)].


About the Autors

Inna Z. Gaydukova, MD, professor of the Department of therapy, rheumatology, temporary incapacity and medical care quality expertise named after E.E. Eichwald of I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia. Address: 191015, Saint Petersburg, 41 Kirochnaya Str. Tel.: +7 (903) 329-03-59. E-mail: ubp1976@list.ru. ORCID 0000-0003-3500-7256
Vadim I. Mazurov, MD, professor, Academician RAS, Chief scientific adviser of I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia, head of the Department of therapy, rheumatology, temporary incapacity and medical care quality expertise named after E.E. Eichwald of I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia, head of St. Petersburg Center of autoimmune disease, Honored worker of science of the Russian Federation. Address: 191015, Saint Petersburg, 41 Kirochnaya Str. Tel.: +7 (921) 951-71-88. E-mail: maz.nwgmu@yandex.ru. ORCID: 0000-0002-0797-2051


Similar Articles

Back to Content

Бионика Медиа